skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Augmentation of radiation response with the vascular targeting agent ZD6126

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [2];  [2];  [3];  [2]
  1. Hematology/Oncology Division, Ohio State University College of Medicine, Columbus, OH (United States)
  2. Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, Wisconsin (United States)
  3. Department of Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, WI (United States)

Purpose: To examine the antivascular and antitumor activity of the vascular targeting agent ZD6126 in combination with radiation in lung and head-and-neck (H and N) cancer models. The overall hypothesis was that simultaneous targeting of tumor cells (radiation) and tumor vasculature (ZD6126) might enhance tumor cell killing. Methods and Materials: A series of in vitro studies using human umbilical vein endothelial cells (HUVEC) and in vivo studies in athymic mice bearing human lung (H226) and H and N (squamous cell carcinoma [SCC]1, SCC6) tumor xenografts treated with ZD6126 and/or radiation were performed. Results: ZD6126 inhibited the capillary-like network formation in HUVEC. Treatment of HUVEC with ZD6126 resulted in cell cycle arrest in G2/M, with decrease of cells in S phase and proliferation inhibition in a dose-dependent manner. ZD6126 augmented the cell-killing effect of radiation and radiation-induced apoptosis in HUVEC. The combination of ZD6126 and radiation further decreased tumor vascularization in an in vivo Matrigel angiogenesis assay. In tumor xenografts, ZD6126 enhanced the antitumor activity of radiation, resulting in tumor growth delay. Conclusions: These preclinical studies suggest that ZD6126 can augment the radiation response of proliferating endothelial H and N and lung cancer cells. These results complement recent reports suggesting the potential value of combining radiation with vascular targeting/antiangiogenic agents.

OSTI ID:
20793432
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 64, Issue 5; Other Information: DOI: 10.1016/j.ijrobp.2005.11.017; PII: S0360-3016(05)02967-6; Copyright (c) 2006 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors
Journal Article · Fri Jul 01 00:00:00 EDT 2005 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20793432

Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice
Journal Article · Thu Mar 01 00:00:00 EST 2007 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20793432

Targeted Therapy Against VEGFR and EGFR With ZD6474 Enhances the Therapeutic Efficacy of Irradiation in an Orthotopic Model of Human Non-Small-Cell Lung Cancer
Journal Article · Sat Dec 01 00:00:00 EST 2007 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20793432